tirzepatide and nash Nearly 62% achieve MASH resolution without worsening of fibrosis with Tirzepatide GLP-1/GIP Mechanism & Metabolic

It is important to appreciate, however, that the increased risk relates to a disorder that is relatively uncommon. He went on to say: Our findings should be viewed as being significant but tentative, as future studies are needed to examine these questions in a much larger and more diverse population

Of the tirzepatide group, 89% achieved a weight loss of at least 5% compared with 28% in the placebo group

Lehti, M

10.1016/0014-5793(96)00332-8 56 Iturbe-OrmaetxeI.MatamorosM

They kind of, you know, they're divorced and don't

May your starting dose stay smooth, your titration stay steady, and your results stay lasting.